|
1
|
Crotti S, Piccoli M, Rizzolio F, Giordano
A, Nitti D and Agostini M: Extracellular matrix and colorectal
cancer: How surrounding microenvironment affects cancer cell
behavior? J Cell Physiol. 232:967–975. 2017. View Article : Google Scholar
|
|
2
|
Colon Cancer Treatment: (PDQ(R)): Health
Professional Version: PDQ Cancer Information Summaries. Bethesda
(MD): 2002
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pattison AM, Merlino DJ, Blomain ES and
Waldman SA: Guanylyl cyclase C signaling axis and colon cancer
prevention. World J Gastroenterol. 22:8070–8077. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yue PY, Wong DY, Wu PK, Leung PY, Mak NK,
Yeung HW, Liu L, Cai Z, Jiang ZH, Fan TP, et al: The
angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem
Pharmacol. 72:437–445. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fan F, Schimming A, Jaeger D and Podar K:
Targeting the tumor microenvironment: Focus on angiogenesis. J
Oncol. 2012:2812612012. View Article : Google Scholar
|
|
7
|
Ferrara N, Hillan KJ and Novotny W:
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody
for cancer therapy. Biochem Biophys Res Commun. 333:328–335. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen QJ, Zhang MZ and Wang LX: Gensenoside
Rg3 inhibits hypoxia-induced VEGF expression in human cancer cells.
Cell Physiol Biochem. 26:849–858. 2010. View Article : Google Scholar
|
|
9
|
Junmin S, Hongxiang L, Zhen L, Chao Y and
Chaojie W: Ginsenoside Rg3 inhibits colon cancer cell migration by
suppressing nuclear factor kappa B activity. J Tradit Chin Med.
35:440–444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan HD, Quan HY, Zhang Y, Kim SH and
Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon
cancer cells is associated with AMPK signaling pathway. Mol Med
Rep. 3:825–831. 2010.
|
|
11
|
Li W, Xie L, Chen Z, Zhu Y, Sun Y, Miao Y,
Xu Z and Han X: Cantharidin, a potent and selective PP2A inhibitor,
induces an oxidative stress-independent growth inhibition of
pancreatic cancer cells through G2/M cell-cycle arrest and
apoptosis. Cancer Sci. 101:1226–1233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang J, Chen C, Wang S, Zhang Y, Yin P,
Gao Z, Xu J, Feng D, Zuo Q, Zhao R, et al: Bufalin inhibits HCT116
colon cancer cells and its orthotopic xenograft tumor in mice model
through genes related to apoptotic and PTEN/AKT pathways.
Gastroenterol Res Pract. 2015:4571932015. View Article : Google Scholar
|
|
13
|
Wahab SMR, Islam F, Gopalan V and Lam AK:
The identifications and clinical implications of cancer stem cells
in colorectal cancer. Clin Colorectal Cancer. 16:93–102. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cherciu I, Bărbălan A, Pirici D,
Mărgăritescu C and Săftoiu A: Stem cells, colorectal cancer and
cancer stem cell markers correlations. Curr Health Sci J.
40:153–161. 2014.
|
|
15
|
Vaiopoulos AG, Kostakis ID, Koutsilieris M
and Papavassiliou AG: Colorectal cancer stem cells. Stem Cells.
30:363–371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ren F, Sheng WQ and Du X: CD133: A cancer
stem cells marker, is used in colorectal cancers. World J
Gastroenterol. 19:2603–2611. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu L, Zhi Q, Shen M, Gong FR, Zhou BP,
Lian L, Shen B, Chen K, Duan W, Wu MY, et al: FH535, a β-catenin
pathway inhibitor, represses pancreatic cancer xenograft growth and
angiogenesis. Oncotarget. 7:47145–47162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang WJ, Wu MY, Shen M, Zhi Q, Liu ZY,
Gong FR, Tao M and Li W: Cantharidin and norcantharidin impair
stemness of pancreatic cancer cells by repressing the β-catenin
pathway and strengthen the cytotoxicity of gemcitabine and
erlotinib. Int J Oncol. 47:1912–1922. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reim F, Dombrowski Y, Ritter C, Buttmann
M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl
J, et al: Immunoselection of breast and ovarian cancer cells with
trastuzumab and natural killer cells: Selective escape of
CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res.
69:8058–8066. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Güveli ME, Duranyildiz D, Karadeniz A,
Bilgin E, Serilmez M, Soydinc HO and Yasasever V: Circulating serum
levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and
larynx carcinoma patients. Tumour Biol. 37:8979–8983. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamaguchi A, Nozawa K, Fujishiro M,
Kawasaki M, Suzuki F, Takamori K, Ogawa H, Takasaki Y and Sekigawa
I: CC motif chemokine ligand 13 is associated with rheumatoid
arthritis pathogenesis. Mod Rheumatol. 23:856–863. 2013. View Article : Google Scholar
|
|
22
|
Lai TH, Wu PH and Wu WB: Involvement of
NADPH oxidase and NF-κB activation in CXCL1 induction by vascular
endothelial growth factor in human endometrial epithelial cells of
patients with adenomyosis. J Reprod Immunol. 118:61–69. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo X, Pan Q, Liu L and Chegini N: Genomic
and proteomic profiling II: Comparative assessment of gene
expression profiles in leiomyomas, keloids, and surgically-induced
scars. Reprod Biol Endocrinol. 5:352007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kameyama H, Udagawa O, Hoshi T, Toukairin
Y, Arai T and Nogami M: The mRNA expressions and
immunohistochemistry of factors involved in angiogenesis and
lymphangiogenesis in the early stage of rat skin incision wounds.
Leg Med (Tokyo). 17:255–260. 2015. View Article : Google Scholar
|
|
25
|
Hung MS, Chen IC, Lin PY, Lung JH, Li YC,
Lin YC, Yang CT and Tsai YH: Epidermal growth factor receptor
mutation enhances expression of vascular endothelial growth factor
in lung cancer. Oncol Lett. 12:4598–4604. 2016.
|
|
26
|
Zhang Z, Wang L, Du J, Li Y, Yang H, Li C,
Li H and Hu H: Lipid raft localization of epidermal growth factor
receptor alters matrix metalloproteinase-1 expression in SiHa cells
via the MAPK/ERK signaling pathway. Oncol Lett. 12:4991–4998.
2016.
|
|
27
|
Yan H, Sun R, Pan X, Li Z, Guo X and Gao
L: Lack of association between an insertion/deletion polymorphism
in IL1A and risk of colorectal cancer. Genet Mol Res. 14:8490–8495.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Akrami H, Mahmoodi F, Havasi S and Sharifi
A: PlGF knockdown inhibited tumor survival and migration in gastric
cancer cell via PI3K/Akt and p38MAPK pathways. Cell Biochem Funct.
34:173–180. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dopheide JF, Geissler P, Rubrech J, Trumpp
A, Zeller GC, Bock K, Dorweiler B, Dünschede F, Münzel T, Radsak
MP, et al: Inflammation is associated with a reduced number of
pro-angiogenic Tie-2 monocytes and endothelial progenitor cells in
patients with critical limb ischemia. Angiogenesis. 19:67–78. 2016.
View Article : Google Scholar
|
|
30
|
Koukourakis GV and Sotiropoulou-Lontou A:
Targeted therapy with bevacizumab (Avastin) for metastatic
colorectal cancer. Clin Transl Oncol. 13:710–714. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bennouna J, Sastre J, Arnold D, Österlund
P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C,
et al: ML18147 Study Investigators: Continuation of bevacizumab
after first progression in metastatic colorectal cancer (ML18147):
A randomised phase 3 trial. Lancet Oncol. 14:29–37. 2013.
View Article : Google Scholar
|
|
32
|
Chen Z, Pang N, Du R, Zhu Y, Fan L, Cai D,
Ding Y and Ding J: Elevated expression of programmed death-1 and
programmed death Ligand-1 negatively regulates immune response
against cervical cancer cells. Mediators Inflamm. 2016:68914822016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bryan LJ and Gordon LI: Releasing the
brake on the immune system: The PD-1 strategy for hematologic
malignancies. Oncology (Williston Park). 29:431–439. 2015.
|
|
34
|
Baptista MZ, Sarian LO, Derchain SF, Pinto
GA and Vassallo J: Prognostic significance of PD-L1 and PD-L2 in
breast cancer. Hum Pathol. 47:78–84. 2016. View Article : Google Scholar
|
|
35
|
Reiss KA, Forde PM and Brahmer JR:
Harnessing the power of the immune system via blockade of PD-1 and
PD-L1: A promising new anticancer strategy. Immunotherapy.
6:459–475. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ghebeh H, Mohammed S, Al-Omair A, Qattan
A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah
A, et al: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is
expressed in breast cancer patients with infiltrating ductal
carcinoma: Correlation with important high-risk prognostic factors.
Neoplasia. 8:190–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun M, Richards S, Prasad DV, Mai XM,
Rudensky A and Dong C: Characterization of mouse and human B7-H3
genes. J Immunol. 168:6294–6297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chapoval AI, Ni J, Lau JS, Wilcox RA,
Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, et al: B7-H3: A
costimulatory molecule for T cell activation and IFN-gamma
production. Nat Immunol. 2:269–274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Steinberger P, Majdic O, Derdak SV,
Pfistershammer K, Kirchberger S, Klauser C, Zlabinger G, Pickl WF,
Stöckl J and Knapp W: Molecular characterization of human 4Ig-B7-H3
a member of the B7 family with four Ig-like domains. J Immunol.
172:2352–2359. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu H, Cheung IY, Guo HF and Cheung NK:
MicroRNA miR-29 modulates expression of immunoinhibitory molecule
B7-H3: Potential implications for immune based therapy of human
solid tumors. Cancer Res. 69:6275–6281. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang F, Wang G, Liu T, Yu G, Zhang G and
Luan X: B7-H3 was highly expressed in human primary hepatocellular
carcinoma and promoted tumor progression. Cancer Invest.
32:262–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ingebrigtsen VA, Boye K, Nesland JM,
Nesbakken A, Flatmark K and Fodstad Ø: B7-H3 expression in
colorectal cancer: Associations with clinicopathological parameters
and patient outcome. BMC Cancer. 14:6022014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Maeda N, Yoshimura K, Yamamoto S, Kuramasu
A, Inoue M, Suzuki N, Watanabe Y, Maeda Y, Kamei R, Tsunedomi R, et
al: Expression of B7-H3 a potential factor of tumor immune evasion
in combination with the number of regulatory T cells, affects
against recurrence-free survival in breast cancer patients. Ann
Surg Oncol. 21(Suppl 4): S546–S554. 2014. View Article : Google Scholar
|
|
44
|
Baral A, Ye HX, Jiang PC, Yao Y and Mao Y:
B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor
tissue correlates with the malignancy grade of glioma patients.
Oncol Lett. 8:1195–1201. 2014.PubMed/NCBI
|
|
45
|
Ingebrigtsen VA, Boye K, Tekle C, Nesland
JM, Flatmark K and Fodstad O: B7-H3 expression in colorectal
cancer: nuclear localization strongly predicts poor outcome in
colon cancer. Int J Cancer. 131:2528–2536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yamato I, Sho M, Nomi T, Akahori T,
Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H and Nakajima Y:
Clinical importance of B7-H3 expression in human pancreatic cancer.
Br J Cancer. 101:1709–1716. 2009. View Article : Google Scholar : PubMed/NCBI
|
